Healthcare
Tectonic Therapeutic, Inc.(TECX)
Live Price
Offline$30.02
-0.13% today
1Y Change
+48.36%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $550.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -3.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tectonic Therapeutic, Inc. (TECX) is a Healthcare stock with a market cap of $550.00M and listed on NASDAQ. The stock last traded around $30.02 and up 48.4% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -3.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -3.1%, free cash flow -1.8% with operating margin 0.0% and ROIC -33.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TECX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 7, 2026 with an EPS surprise of -15.5%.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -3.1%, with operating margin around 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | -15.5% | +7.9% | +10.9% | +7.9% |
2026 Feb 26, 2026 | +7.2% | -2.0% | +16.4% | +28.5% |
2025 Nov 6, 2025 | +2.9% | +1.7% | -7.4% | +4.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TECX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TECX Max Drawdown
-44.62%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TECX and SPY.
Company Overview
Tectonic Therapeutic, Inc.
NASDAQ Global Market
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
- Leadership
- Alise S. Reicin
- IPO Date
- Jun 21, 2018
- Employees
- 51
- Street Address
- 490 Arsenal Way
- Mailing
- Watertown, MA, 02472
- Region
- Watertown, MA, US
- Reporting Currency
- USD
- Investor Line
- +1 617 830 5233
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.1
Growth
- Revenue
- 0.0%
- EPS
- -3.1%
- Free Cash Flow
- -1.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -26.9%
- ROIC
- -33.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 26.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.